Study of the oral FLT3/AXL inhibitor gilteritinib for AML to move forwards
Midostaurin: the first drug to receive approval for AML since 2000
New trends in the management of leukemia
May the force be with you: the power of next-generation sequencing
MRD for acute leukemias: opinion from both sides of the Atlantic
Alan Burnett et al.